A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

by | Jun 16, 2025 | Clinical Trials | 0 comments

​ Conditions: Colorectal Cancer

Interventions: Drug: Telisotuzumab Adizutecan; Drug: Standard of Care

Sponsors: AbbVie

Not yet recruiting Conditions: Colorectal Cancer
Interventions: Drug: Telisotuzumab Adizutecan; Drug: Standard of Care
Sponsors: AbbVie
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *